Breaking News Instant updates and real-time market news.

AVXS

AveXis

$210.46

94.55 (81.57%)

, NVS

Novartis

$81.07

0.87 (1.08%)

16:25
04/09/18
04/09
16:25
04/09/18
16:25

On The Fly: Top stock stories for Monday

Stocks opened in positive territory and moved higher through much of the day before paring most of their gains late in the session. There was little from a macro standpoint as the economic calendar was quiet and the toned-down tariff talk over the weekend seemed to embolden buyers, at least for a while. Investors are preparing for the earnings season, which will begin at the end of the week with several big banks' reports. ECONOMIC EVENTS: In the U.S., no data of note was reported. COMPANY NEWS: Shares of AveXis (AVXS) jumped 81.5% to close at $210.46 after the gene therapy researcher announced an agreement to be acquired by Novartis (NVS) for $218 per share, or $8.7B in cash. Strength in several other mid-late stage gene therapy players, including Regenxbio (RGNX), was attributed to read-through from the large premium paid for AveXis... Meanwhile, the Department of Justice has decided to allow Bayer's (BAYRY) acquisition of Monsanto (MON) after the companies pledged to sell off additional assets, The Wall Street Journal reported, citing people familiar with the matter. Shares of Monsanto ended the day 6% higher following the story. MAJOR MOVERS: Among the notable gainers was Jounce Therapeutics (JNCE), which gained 7% following a Financial Times report that suggested the company and Agios Pharmaceuticals (AGIO) could be potential acquisition targets for Celgene (CELG). Also higher was Leucadia (LUK), which gained 11.5% after announcing strategic transactions involving several of its investee companies, a proposal to change the name of the corporation to Jefferies Financial Group, a new share buyback authorization and preliminary results for its first quarter 2018. Among the noteworthy losers was Menlo Therapeutics (MNLO), which dropped 77% after the company announced its Phase 2 clinical trial of serlopitant did not meet its primary or key secondary endpoints. Also lower were shares of Acadia Pharmaceuticals (ACAD), which fell 23% after an investigative report from CNN raised questions about FDA data regarding the number of reported deaths seen among patients taking the Parkinson's drug Nuplazid. INDEXES: The Dow rose 46.34, or 0.19%, to 23,979.10, the Nasdaq gained 35.23, or 0.51%, to 6,950.34, and the S&P 500 advanced 8.69, or 0.33%, to 2,613.16.

AVXS

AveXis

$210.46

94.55 (81.57%)

NVS

Novartis

$81.07

0.87 (1.08%)

RGNX

Regenxbio

$31.45

4.25 (15.63%)

MON

Bought by BAYRY

$125.15

7.29 (6.19%)

BAYRY

Bayer

$29.30

0.65 (2.27%)

JNCE

Jounce Therapeutics

$19.78

1.3 (7.03%)

AGIO

Agios Pharmaceuticals

$80.00

6.78 (9.26%)

CELG

Celgene

$86.94

-0.01 (-0.01%)

MNLO

Menlo Therapeutics

$8.17

-27.05 (-76.80%)

ACAD

Acadia

$16.50

-5.03 (-23.36%)

LUK

Leucadia

$24.29

2.52 (11.58%)

  • 09

    Apr

  • 09

    Apr

  • 13

    Apr

  • 14

    Apr

  • 16

    Apr

  • 20

    Apr

  • 23

    Apr

  • 04

    May

  • 08

    May

  • 17

    May

  • 18

    May

  • 23

    May

  • 30

    May

  • 21

    Aug

  • 04

    Oct

AVXS AveXis
$210.46

94.55 (81.57%)

04/09/18
JEFF
04/09/18
NO CHANGE
JEFF
Jefferies highlights other gene theraphy players after AveXis takeover
Novartis' (NVS) deal to acquire AveXis (AVXS) for $8.7B should remind investors about the ongoing attractiveness within smid-cap biotech, Jefferies analyst Michael Yee tells investors in a research note. Novartis' two large gene therapy deals in four months will lead to a question of "who's next," the analyst adds. Yee says other mid-late stage gene therapy players include Bluebird Bio (BLUE), Spark Therapeutics (ONCE), BioMarin (BMRN), Abeona Therapeutics (ABEO), Regenxbio (RGNX), Nightstar Therapeutics (NITE) and Voyager Therapeutics (VYGR).
04/09/18
WBLR
04/09/18
DOWNGRADE
WBLR
Market Perform
AveXis downgraded to Market Perform from Outperform at William Blair
William Blair analyst Raju Prasad downgraded AveXis (AVXS) to Market Perform after the company reached an agreement to be acquired by Novartis (NVS).
04/09/18
MSCO
04/09/18
DOWNGRADE
MSCO
Equal Weight
AveXis downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz downgraded AveXis (AVXS) to Equal Weight from Overweight following its announcement of an agreement to be acquired by Novartis (NVS) for $218 per share. He added that the buyout premium AveXis garnered should benefit Regenxbio (RGNX) as well.
04/09/18
NOMU
04/09/18
UPGRADE
NOMU
Neutral
AveXis upgraded to Neutral from Reduce at Nomura Instinet
Nomura Instinet analyst Christopher Marai upgraded AveXis (AVXS) to Neutral after the company agreed to be acquired by Novartis (NVS) for $218 per share.
NVS Novartis
$81.07

0.87 (1.08%)

04/09/18
JEFF
04/09/18
NO CHANGE
JEFF
Buy
Jefferies ponders other potential suitors for AveXis after Novartis deal
Jefferies analyst Biren Amin asks who else can jump into the mix after AveXis (AVXS) agreed to be acquired by Novartis (NVS) for $218 per share in an all-cash deal. The analyst, who does not expect anti-trust issues to arise with the deal on the table, notes the speculation that Biogen (BIIB) may need to evaluate AveXis at some point. The Novartis deal could be the "trigger that forces it to do so," Amin writes in a research note. Further, the analyst has always felt Roche (RHHBY) could have an interest in AveXis given its development program with RG7916. He points out that AveXis Chairman Dan Welch was the CEO of Intermune when Roche purchased the company in 2014 for $8.3B. AveXis in premarket trading is up 81%, or $94.14, to $210.05.
RGNX Regenxbio
$31.45

4.25 (15.63%)

03/12/18
EVER
03/12/18
DOWNGRADE
EVER
In Line
Regenxbio downgraded to In Line from Outperform at Evercore ISI
03/12/18
EVER
03/12/18
DOWNGRADE
Target $35
EVER
In Line
Regenxbio downgraded to In Line on valuation at Evercore ISI
As previously reported, Evercore ISI downgraded Regenxbio to In Line from Outperform and raised its price target to $35 from $30. Analyst Josh Schimmer cites the strong run in shares and notes value of the company will depend heavily on Regenxbio's ability to successfully develop and commercialize its own compelling gene therapy products.
MON Bought by BAYRY
$125.15

7.29 (6.19%)

07/12/17
07/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Monsanto (MON) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying Bayer's (BAYRY) all-cash offer appears on track for year-end. The analyst views the deal failing as a "low-probability scenario" and keeps a $128 price target for the shares. 2. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 3. Kimberly-Clark (KMB) downgraded to Sell from Neutral at UBS with analyst Stephen Powers saying the stock's 11% rise year-to-date is not based on fundamentals but news flow of consolidation in the Household Products sector. 4. Harley-Davidson (HOG) downgraded to Market Perform from Outperform at Bernstein with analyst David Beckel citing his belief that "demographic shifts and a stagnating economy" will prevent demand for the company's motorcycles from growing in the U.S. for the next five years. 5. IMAX (IMAX) downgraded to Market Perform from Outperform at Barrington with analyst James Goss saying positive catalysts "might take some time to develop." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/17
MACQ
10/04/17
DOWNGRADE
MACQ
Neutral
Monsanto downgraded to Neutral from Outperform at Macquarie
09/05/17
BERN
09/05/17
NO CHANGE
BERN
Bernstein still sees 'very high' probability of Bayer, Monsanto deal approval
Bernstein analyst Jeremy Redenius notes that the European Commission has opened an in-depth review of the Bayer (BAYRY)/Monsanto (MON) deal due to concerns of reduced competition in pesticides, seeds, and traits. The analyst believes this is not surprising, as the in-depth review is the norm for deals of this size. Comparing the EC's initial concerns with those of the Dow/DuPont (DWDP) deal, he still sees a "very high" probability of deal approval.
08/18/17
UBSW
08/18/17
DOWNGRADE
Target $128
UBSW
Neutral
Monsanto downgraded to Neutral from Buy at UBS
UBS analyst John Roberts downgraded Monsanto (MON) to Neutral saying the shares are now less than 10% away from the accepted Bayer (BAYRY) offer of $128. The analyst calculates that the market is currently pricing in a 70% chance of the deal going through. His view that the deal could be approved remains unchanged. Approvals of peer deals suggest antitrust approval likely for Monsanto, Roberts tells investors in a research note. The analyst keeps a $128 price target for Monsanto shares.
BAYRY Bayer
$29.30

0.65 (2.27%)

12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/15/17
MSCO
11/15/17
NO CHANGE
Target $103
MSCO
Overweight
Loxo Oncology partnership with Bayer better than recognized, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison thinks Loxo Oncology's (LOXO) partnership with Bayer (BAYRY) is a smart move and points to two key aspects of the deal that are being underappreciated. Namely, the deal offsets the risk of a slow TRK launch while he also believes strategic optionality is still intact as Loxo maintains two fully owned program, Harrison tells investors. Harrison maintains an Overweight rating on Loxo with a $103 price target. The stock slid about 4% yesterday to close at $79.84 after the Bayer deal was announced.
12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
JNCE Jounce Therapeutics
$19.78

1.3 (7.03%)

AGIO Agios Pharmaceuticals
$80.00

6.78 (9.26%)

02/15/18
FBCO
02/15/18
NO CHANGE
Target $80
FBCO
Outperform
Agios Pharmaceuticals price target raised to $80 from $66 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for Agios Pharmaceuticals to $80 from $66 as she sees upside opportunities in her valuation model related to newly diagnosed success in ivosidenib, PKD, AG-270 and DHODH. The analyst reiterates an Outperform rating on the shares.
02/14/18
OPCO
02/14/18
DOWNGRADE
OPCO
Perform
Oppenheimer downgrades Agios on valuation after Q4 results
Oppenheimer analyst Leah Rush Cann downgraded Agios Pharmaceuticals to Perform from Outperform following this morning's Q4 results. The analyst, who rescinded her price target, says that while the company's pipeline programs are moving forward, the shares trade inline with her valuation following the substantial rally over the previous 12 months. Cann adds Agios's recent capital raise resulted in approximately 17% dilution.
02/14/18
OPCO
02/14/18
DOWNGRADE
OPCO
Perform
Agios Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
02/15/18
RHCO
02/15/18
NO CHANGE
Target $101
RHCO
Buy
Agios Pharmaceuticals price target raised to $101 from $80 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Agios Pharmaceuticals to $101, citing increasing value of AG-348 that is expected to begin in Q2 of this year. The analyst also points to AG-270 trial starting in Q1 of this year and a perioperative "window" study of ivosidenib/AG-881 in glioma as potential catalysts. Suneja concludes that 4 Agios Pharmaceuticals is "making rapid progress on al fronts", keeping his Buy rating on the stock.
CELG Celgene
$86.94

-0.01 (-0.01%)

03/28/18
LEER
03/28/18
NO CHANGE
Target $123
LEER
Outperform
Leerink sees 60% upside in Celgene shares under 'base case' scenario
Leerink analyst Geoffrey Porges says his sum-of-the-parts analysis suggests Celgene shares are discounting zero cash flow from Revlimid after 2022 and no approval ever of ozanimod or luspatercept. His "base case" scenario, which includes a slow revenue decline for Revlimid post 2022 and ozanimod's approval in multiple sclerosis during 2019 with a 50% probability of success in all indications, results in a net present value of $140 per share, which is 60% above the current share stock price. Celgene closed yesterday down $1.36 to $85.81. Porges' "worst case" scenario, which assumes no Revlimid contribution post 2022 and neither ozanimod nor luspatercept, has the stock worth $87. Celgene shares discounting "such a bad outlook" is no surprise after the company's "recent missteps and misjudgments," but the stock offers "remarkable upside" to investors willing to step in at the current "distressed" valuation," Porges tells investors in a research note. He keeps an Outperform rating on Celgene with a $123 price target.
04/03/18
JMPS
04/03/18
NO CHANGE
JMPS
Market Perform
Celgene COO departure not a surprise, says JMP Securities
JMP Securities analyst Michael King said he was not surprised by the announcement that Celgene COO Scott Smith is exiting given the recent missteps in the company's Inflammation and Immunology franchise. This appears to be the first major step in restructuring Celgene's executive team and he hopes the evolving management structure improves execution and accountability, King tells investors. Although valuation seems to be at extreme lows, King thinks Celgene shares will have a hard time recovering until the company can demonstrate it has regained its ability to drive value, either through execution or an acquisition. He keeps a Market Perform rating on the stock.
03/27/18
EVER
03/27/18
NO CHANGE
Target $155
EVER
Outperform
Evercore sees higher chances of Revlimid patent settlement for Celgene
Evercore ISI analyst Umer Raffat believes the odds of a Revlimid patent settlement between Celgene (CELG) and Dr. Reddy's (RDY) have gone up "considerably" following a recent court filing. The filing, according to the analyst, shows Dr. Reddy's agreed to resolve claims construction issues, which he believes "implies a clear alignment in thought process between both sides." A potential settlement on Revlimid remains the biggest catalyst on Celgene in 2018, and could lead a quick re-rating in the valuation multiple, Raffat tells investors in a research note. He keeps Celgene as his top pick for 2018 with an Outperform rating and $155 price target.
03/28/18
03/28/18
NO CHANGE

Bluebird Bio and Celegene to co-develop bb2121 anti-BMCA therapy
Bluebird Bio (BLUE) and Celgene (CELG) announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen, or BCMA chimeric antigen receptor, or CAR, T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.The companies originally entered into a broad, global strategic research collaboration in 2013 to discover, develop and commercialize novel therapies in oncology, which included bb2121.
MNLO Menlo Therapeutics
$8.17

-27.05 (-76.80%)

04/09/18
JEFF
04/09/18
DOWNGRADE
Target $20
JEFF
Hold
Menlo Therapeutics downgraded to Hold from Buy at Jefferies
Jefferies analyst David Steinberg downgraded Menlo Therapeutics to Hold and cut his price target for the shares to $20 from $41. The analyst is surprised that the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis did not meet its primary or key secondary efficacy endpoints.
04/09/18
PIPR
04/09/18
NO CHANGE
Target $48
PIPR
Overweight
Piper reiterates Overweight on Menlo Therapeutics after Phase II miss
Piper Jaffray analyst David Amsellem calls Menlo Therapeutics' serlopitant missing the primary and secondary endpoints in a Phase IIb study in patients with pruritis associated with atopic dermatitis as "big disappointment." The analyst, however, does not infer that the setback in atopic dermatitis "necessarily raises the risk" surrounding the prurigo nodularis Phase III trials. Prurigo nodularis is an altogether different condition, Amsellem tells investors in a research note. He believes last night's trial miss "should not call into question the overall viability of serlopitant as an anti-pruritic agent." Amsellem reiterates an Overweight rating on Menlo Therapeutics.
02/20/18
JMPS
02/20/18
INITIATION
Target $44
JMPS
Outperform
Menlo Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis started Menlo Therapeutics with an Outperform rating and $44 price target, nothing that he forecasts launches of treatments of prurigo nodularis, psoriasis and atopic dermatitis in early 2022. Ellis believes the U.S. pruritus market could easily exceed $1B, he tells investors.
02/20/18
02/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Imax (IMAX) assumed with an Overweight at JPMorgan. 2. Gates Industrial (GTES) was initiated with an Outperform at RBC Capital and Credit Suisse, an Overweight at Morgan Stanley and KeyBanc, as well as a Buy at SunTrust, UBS, and Citi. 3. Menlo Therapeutics (MNLO) was initiated with an Outperform at JMP Securities, an Overweight at Piper Jaffray, and a Buy at Jefferies. 4. PlayAGS (AGS) was initiated with a Buy at SunTrust, BofA/Merrill, and Deutsche Bank. 5. PagSeguro Digital (PAGS) was initiated with a Neutral at JPMorgan, BofA/Merrill, UBS, and Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ACAD Acadia
$16.50

-5.03 (-23.36%)

11/06/17
LEER
11/06/17
NO CHANGE
Target $35
LEER
Market Perform
Data suggests Acadia pivotal DRP program is high risk, says Leerink
Following full data from Acadia's phase 2 study of pimavanserin in Alzheimer's Disease Psychosis patients at the Clinical Trials on Alzheimer's Disease, Leerink analyst Paul Matteis says his cautious view on the company's phase 3 dementia related psychosis program remains as the statistically significant benefit for pimavanserin seen at the primary endpoint of 6 weeks was in his view helped considerably by a temporary regression in placebo response, this dynamic was also the case in a featured, more severe subgroup, and dementia related psychosis is a chronic condition, and for any new medication a sustained clinical benefit will be important. He reiterates a Market Perform rating and $35 price target on the shares.
10/05/17
LEER
10/05/17
NO CHANGE
LEER
Market Perform
Acadia Dementia Psychosis BTD a positive surprise, says Leerink
Leerink analyst Paul Matteis notes that Acadia announced the initiation of a phase III study, HARMONY, assessing pimavanserin in various dementia related psychoses. The analyst says that the breadth of the patient population in this pivotal program - previously expected to focus on Alzheimer's Disease - is a "major surprise." Meanwhile, the FDA has granted Breakthrough Therapy Designation, or BTD, to pimavanserin for dementia-related psychosis, Matteis points out, adding that FDA feedback awarding breakthrough designation and allowing for a single pivotal study is encouraging. Moreover, the analyst says that if the study succeeds, the addressable population could be very large. The analyst reiterates a Market Perform rating on the shares.
10/05/17
BOFA
10/05/17
NO CHANGE
Target $46
BOFA
Buy
Acadia price target raised to $46 from $40 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised Acadia's price target to $46 from $40 based on Nuplazid's opportunity for further expansion and continued positive physician feedback on Nuplazid in PDP. The analyst rates Acadia a Buy.
10/05/17
JMPS
10/05/17
NO CHANGE
Target $50
JMPS
Outperform
Acadia price target raised to $50 from $47 at JMP Securities
JMP Securities analyst Jason Butler noted that Acadia's Phase 3 HARMONY trial of pimavanserin is a relapse prevention study, which he contends optimizes the timelines and the potential for success. Butler, who increased his probability of success in the indication of dementia-related psychosis to 65% from 50%, raised his price target on Acadia shares to $50 from $47 and keeps a Outperform rating on the stock.
LUK Leucadia
$24.29

2.52 (11.58%)

TODAY'S FREE FLY STORIES

NXRT

NexPoint Residential

$36.26

0.93 (2.63%)

15:06
11/20/18
11/20
15:06
11/20/18
15:06
Hot Stocks
NexPoint Residential VP Matt McGraner buys over $313K in company shares »

NexPoint Residential VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Periodicals
Trump plans talks with German car executives, Bloomberg says »

The White House has…

BMWYY

BMW

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$24.91

-0.535 (-2.10%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Options
Gap options imply 11.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

D

Dominion

$74.65

0.25 (0.34%)

, SCG

Scana

$44.08

0.38 (0.87%)

15:01
11/20/18
11/20
15:01
11/20/18
15:01
Periodicals
Dominion proposes alternate plan for Scana deal, Bloomberg says »

Bloomberg cites an…

D

Dominion

$74.65

0.25 (0.34%)

SCG

Scana

$44.08

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$11.27

-0.865 (-7.13%)

15:00
11/20/18
11/20
15:00
11/20/18
15:00
Options
Active trading in US Oil Fund options as crude oil drops 7% »

Active trading in US Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
11/20/18
11/20
15:00
11/20/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:56
11/20/18
11/20
14:56
11/20/18
14:56
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Durable Goods Preview »

U.S. Durable Goods…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Existing Home Sales Preview »

U.S. Existing Home Sales…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Michigan Consumer Sentiment Preview »

U.S. Michigan Consumer…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Leading Indicators Preview »

U.S. Leading Indicators…

FB

Facebook

$131.60

-0.02 (-0.02%)

14:53
11/20/18
11/20
14:53
11/20/18
14:53
Periodicals
Dashboard to track time wasted on Facebook starts roll out, Venture Beat says »

Facebook has confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:52
11/20/18
11/20
14:52
11/20/18
14:52
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

XRT

S&P Retail Index SPDR

$44.32

-1.2 (-2.64%)

14:50
11/20/18
11/20
14:50
11/20/18
14:50
Options
SPDR Retail Trust options are active ahead of Black Friday »

SPDR Retail Trust options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$122.41

-3.34 (-2.66%)

14:49
11/20/18
11/20
14:49
11/20/18
14:49
Options
Autodesk options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

  • 04

    Dec

EQT

EQT Corporation

$16.81

-0.25 (-1.47%)

14:45
11/20/18
11/20
14:45
11/20/18
14:45
Options
EQT Corporation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.78

-0.635 (-3.87%)

14:35
11/20/18
11/20
14:35
11/20/18
14:35
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDX

Celldex

$0.31

-0.0002 (-0.06%)

14:32
11/20/18
11/20
14:32
11/20/18
14:32
Hot Stocks
Celldex announces launch of Chase Offers »

Cardlytics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

, VLKAY

Volkswagen

$0.00

(0.00%)

14:32
11/20/18
11/20
14:32
11/20/18
14:32
Periodicals
Trump plans talks with German car executives, Bloomberg says »

German carmakers include…

DDAIF

Daimler AG

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAMXY

BMW Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$33.87

-0.75 (-2.17%)

14:31
11/20/18
11/20
14:31
11/20/18
14:31
Hot Stocks
Mylan says has discontinued a number of products from Morgantown site »

Mylan commented on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 04

    Dec

NAVI

Navient

$11.20

-0.79 (-6.59%)

14:31
11/20/18
11/20
14:31
11/20/18
14:31
Periodicals
DOE audit in 2017 found deceptive practices at Navient, AP reports »

A 2017 audit done by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NAVI

Navient

$11.45

-0.54 (-4.50%)

14:27
11/20/18
11/20
14:27
11/20/18
14:27
Hot Stocks
Breaking Hot Stocks news story on Navient »

Navient down 8% to $11.06…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NAVI

Navient

$11.45

-0.54 (-4.50%)

14:26
11/20/18
11/20
14:26
11/20/18
14:26
Periodicals
Breaking Periodicals news story on Navient »

DOE audit found deceptive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

14:25
11/20/18
11/20
14:25
11/20/18
14:25
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss the U.S.…

ROST

Ross Stores

$84.39

-6.8 (-7.46%)

14:24
11/20/18
11/20
14:24
11/20/18
14:24
Recommendations
Ross Stores analyst commentary  »

Ross Stores price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.